Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
暂无分享,去创建一个
B. Horne | D. Lappé | J. Carlquist | Jeffrey L. Anderson | J. Muhlestein | Matthew J. Kolek | Jeffrey L. Anderson | John F. Carlquist | Benjamin D. Horne | Joseph B. Muhlestein | Donald L. Lappé | Bryant M. Whiting | Matthew J. Kolek | Jessica L. Clarke | Brent C. James | Brent C. James | B. James | Bryant M. Whiting | Jessica L. Clarke | Jeffrey L. Anderson | John F. Carlquist | Matthew J. Kolek | J. Anderson
[1] A. Khvorova,et al. Identification of the gene for vitamin K epoxide reductase , 2004, Nature.
[2] Jon Emery,et al. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.
[3] K. Bachmann. Genotyping and Phenotyping the Cytochrome P-450 Enzymes , 2002, American journal of therapeutics.
[4] W. Weeks,et al. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. , 2000, Effective clinical practice : ECP.
[5] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[6] G. Koch,et al. Potential anticoagulant drug interactions in ambulatory patients , 1978, Clinical pharmacology and therapeutics.
[7] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[8] M. Ingelman-Sundberg,et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.
[9] J. Carlquist,et al. Pharmacogenomics in Cardiovascular Medicine , 2004 .
[10] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[11] L. Wienkers,et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.
[12] H Furuya,et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.
[13] T. Baglin,et al. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.
[14] A. Motulsky,et al. Equal proportion of adult male and female homozygous for the 677C → T mutation in the methylenetetrahydrofolate reductase polymorphism , 2005, American journal of medical genetics. Part A.
[15] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[16] R. Beyth,et al. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. , 1993, The American journal of medicine.
[17] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[18] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[19] J. Caro. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. , 2004, The American journal of managed care.
[20] O. Wallerman,et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors , 2004, The Pharmacogenomics Journal.
[21] M H Tarbit,et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.